NCT04045847

CD147-CART Cells in Patients With Recurrent Malignant Glioma.

A Clinical Study to Investigate the Safety, Tolerance and Efficacy Evaluation of Single-centre, Open-label of Local Treatment of CD147-CART in Recurrent Glioblastoma.

• Status: Unknown
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 31 (estimated)
• Sponsor: Xijing Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a single-center, single-arm, open label and dose escalation clinical study of anti-CD147 CART cells in patients with recurrent malignant glioma.

Detailed description

Patients autologous T cells are activated and then engineered to express chimeric antigen receptors (CARs) specific for CD147(CD147-CART). CAR-T cells are expanded in culture and returned to the patient by Ommaya Reservoir at specific cell doses. Three CD147-CART doses patient are planned at 1-week intervals. Serum cytokine level and CAR-T cell number will be measured in whole treatment session.

Conditions

• Recurrent Glioblastoma
• CD147 Positive

Interventions

Type	Name	Description
BIOLOGICAL	CD147-CART	Three doses of CD147-CART cells were injection to intracavity by Ommaya Reservoir.

Timeline

• Start date: 2019-05-30
• Primary completion: 2020-10-30
• Completion: 2022-05-30
• First posted: 2019-08-06
• Last updated: 2020-05-07

Locations

1 site across 1 country: China